Wedbush Increases Earnings Estimates for Fate Therapeutics

Fate Therapeutics, Inc. (NASDAQ:FATE) – Equities researchers at Wedbush increased their Q1 2025 EPS estimates for Fate Therapeutics in a research report issued on Wednesday, March 5th. Wedbush analyst D. Nierengarten now forecasts that the biopharmaceutical company will earn ($0.42) per share for the quarter, up from their previous forecast of ($0.49). Wedbush has a “Neutral” rating and a $5.00 price target on the stock. The consensus estimate for Fate Therapeutics’ current full-year earnings is ($1.63) per share. Wedbush also issued estimates for Fate Therapeutics’ Q2 2025 earnings at ($0.43) EPS, Q3 2025 earnings at ($0.45) EPS, Q4 2025 earnings at ($0.33) EPS, FY2025 earnings at ($1.63) EPS, FY2026 earnings at ($1.30) EPS and FY2028 earnings at ($1.84) EPS.

Several other equities research analysts also recently commented on FATE. Stifel Nicolaus reduced their price target on shares of Fate Therapeutics from $5.00 to $3.00 and set a “hold” rating for the company in a research report on Thursday, March 6th. Wells Fargo & Company reduced their price target on shares of Fate Therapeutics from $5.00 to $4.00 and set an “equal weight” rating for the company in a research report on Thursday, March 6th. StockNews.com lowered shares of Fate Therapeutics from a “hold” rating to a “sell” rating in a research note on Tuesday. Bank of America upgraded shares of Fate Therapeutics from an “underperform” rating to a “neutral” rating in a research note on Monday, November 18th. Finally, Needham & Company LLC reiterated a “hold” rating on shares of Fate Therapeutics in a research note on Thursday, March 6th. One equities research analyst has rated the stock with a sell rating, seven have given a hold rating and two have given a buy rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Hold” and an average price target of $5.50.

Fate Therapeutics Stock Performance

Shares of NASDAQ:FATE opened at $0.96 on Monday. The company has a market cap of $110.00 million, a PE ratio of -0.58 and a beta of 2.26. Fate Therapeutics has a 52 week low of $0.87 and a 52 week high of $8.27. The firm has a 50 day simple moving average of $1.34 and a 200 day simple moving average of $2.31.

Fate Therapeutics (NASDAQ:FATE) last issued its quarterly earnings results on Wednesday, March 5th. The biopharmaceutical company reported ($0.31) EPS for the quarter, beating the consensus estimate of ($0.44) by $0.13. The business had revenue of $1.86 million during the quarter, compared to the consensus estimate of $1.57 million. Fate Therapeutics had a negative net margin of 1,325.43% and a negative return on equity of 45.88%.

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the business. Graham Capital Management L.P. acquired a new position in Fate Therapeutics in the 4th quarter valued at $37,000. China Universal Asset Management Co. Ltd. acquired a new position in Fate Therapeutics in the 4th quarter valued at $40,000. Brevan Howard Capital Management LP acquired a new position in Fate Therapeutics in the 4th quarter valued at $41,000. FPC Investment Advisory Inc. acquired a new position in Fate Therapeutics in the 4th quarter valued at $44,000. Finally, Point72 Asia Singapore Pte. Ltd. acquired a new position in Fate Therapeutics in the 4th quarter valued at $55,000. Institutional investors and hedge funds own 97.54% of the company’s stock.

Insider Transactions at Fate Therapeutics

In other Fate Therapeutics news, Director Redmile Group, Llc purchased 397,964 shares of the company’s stock in a transaction dated Friday, December 20th. The shares were bought at an average price of $1.68 per share, for a total transaction of $668,579.52. Following the purchase, the director now directly owns 12,884,277 shares in the company, valued at $21,645,585.36. This trade represents a 3.19 % increase in their position. The purchase was disclosed in a legal filing with the SEC, which can be accessed through this link. 5.00% of the stock is currently owned by company insiders.

About Fate Therapeutics

Fate Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma, and FT522, to treat lymphoma and autoimmune disorders.